AN

Anthony Noble

Xenitra Limited | Non-Executive Director, Non-Executive Chairman
Dr Noble has Board experience having previously been the CEO of Australian Biotherapeutics from 2019-2021, a manufacturer of live biotherapeutics based in Coolum Beach, Queensland. He worked at SFI Health from 2010-2019 and held roles as Managing Director of SFI Research Pty Ltd, as Global Head of Innovation, Group Head of North Asia and as General Manager of the SFI-Shineway Chinese Joint Venture. SFI acquired and integrated Ginsana SA (Switzerland), Prothera Inc (USA), Complementary Prescriptions (USA) and Potters Herbals (UK) over this time. He was Principal Scientist, for Cryosite Ltd (Australian Cord Blood Service) and a lead inspector for the Human Tissue Authority (UK).

Company and Roles

Company
Title
Tenure
Since
XEN
XEN
Xenitra Limited
  • Non-Executive Director
  • Non-Executive Chairman
1yrs, 4mthFeb 2025

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
XEN
XEN
Xenitra Limited
02/04/260N/A40,000,000N/A
CCO
CCO
30/06/2511,706,0603,428,6784,580,964N/A
AUK
AUK
28/02/250N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
XEN
XEN
Xenitra Limited
02/04/26
Issued
40,000,000$0.003$120,000Issue of options
CCO
CCO
16/05/25
Issued
1,681,639$0.003$5,044Rights issue
CCO
CCO
16/05/25
Issued
761,929$0.003$2,285Rights issue
CCO
CCO
16/05/25
Issued
2,601,347$0.003$7,804Rights issue
CCO
CCO
10/12/24
Issued
2,386,440$0.007$16,705Placement